ImmunoGen Announces Webcast of Presentation and Q&A at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

ImmunoGen, Inc. (NASDAQ: IMGN) announced that President and CEO Mark Enyedy will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 10, 2023, at 3:45 PM PT. Following the presentation, a Q&A session will take place at 4:05 PM PT. The live webcast will be available via the company’s website, with a replay accessible afterward. ImmunoGen aims to develop next-generation antibody-drug conjugates to enhance cancer treatment and improve patient outcomes as part of their initiative TARGET A BETTER NOW™.

Positive

• Scheduled presentation at prestigious J.P. Morgan Healthcare Conference, increasing visibility.
• Focus on developing next-generation antibody-drug conjugates indicates strong R&D commitment.

Negative

• None.

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 41^st Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation is scheduled for 3:45pm PT (6:45pm ET) on January 10, 2023.

Following the presentation, Mr. Enyedy will be joined by other members of ImmunoGen’s management team for a question-and-answer session at 4:05pm PT (7:05pm ET).

A webcast of the presentation and question-and-answer session will be accessible live through the “Investors & Media” section of the Company’s website, www.immunogen.com; a replay will be available in the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221227005216/en/

INVESTOR RELATIONS

ImmunoGen

Anabel Chan

781-895-0600

anabel.chan@immunogen.com

MEDIA

ImmunoGen

Courtney O'Konek

781-895-0600

courtney.okonek@immunogen.com

OR

FTI Consulting

Robert Stanislaro

212-850-5657

robert.stanislaro@fticonsulting.com

Source: ImmunoGen, Inc.

FAQ

When will ImmunoGen present at the J.P. Morgan Healthcare Conference?

ImmunoGen will present on January 10, 2023, at 3:45 PM PT.

Where is the J.P. Morgan Healthcare Conference taking place?

The conference is being held in San Francisco, CA.

What is ImmunoGen's focus in cancer treatment?

ImmunoGen is focused on developing next-generation antibody-drug conjugates to improve cancer patient outcomes.

Will there be a Q&A session after the presentation?

Yes, a Q&A session will follow the presentation at 4:05 PM PT.

How can I access the webcast of the ImmunoGen presentation?

The webcast will be available live on ImmunoGen’s website in the 'Investors & Media' section.